Price achieved for first indication vs. ASMR
CRA Life Sciences continues its series on leveraging RADAR, its orphan drug data repository, with a focus on PMA trends between ASMR outcomes and average annual
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Strategy in rare disease requires specialist expertise and understanding. CRA understands the unique challenges that rare disease companies face, and we implement a distinctive approach to help drive their success.
Follow us on LinkedIn: CRA on Rare Disease
CRA’s experience stems from hundreds of rare disease engagements across many therapeutic areas.
CRA Life Sciences continues its series on leveraging RADAR, its orphan drug data repository, with a focus on PMA trends between ASMR outcomes and average annual
Although rare diseases affect a relatively small number of patients, collectively there are an estimated 30 million people in Europe living with 6,000-7,000...
CRA’s Clara Zacharko will be presenting a CRA study on an ISPOR webinar titled “The Global Socioeconomic Impact of Rare Diseases: A Call for Action” on May...
CRA is exhibiting at the conference at booth #2018. Matt Majewski presents his session titled “What is a Fair Price for a Rare Disease Therapy?”...